<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2204257267
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        APO-DOXY 100MG CAPS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOXYCYCLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        28.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apo-Doxy is a broad-spectrum antibiotic.</p><p>It is used in the treatment of a variety of infections caused by susceptible strains of Gram-positive and Gram-negative bacteria and certain other micro-organisms.</p><p>It may be used to treat a wide range of infections caused by bacteria; these include Pneumonia, Other Respiratory Tract Infections, Genitourinary Tract Infections, Skin and Soft Tissue Infections &amp; Gastro-intestinal Infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- Do not take APO-DOXY if:</strong></p><ul><li>You are allergic to any of the ingredients listed at the beginning of this leaflet&nbsp;</li><li>You have myasthenia gravis (a chronic autoimmune neuromuscular disease which cause muscle weakness)</li></ul><p>&nbsp;</p><p><strong>b- Take special care:</strong></p><p>You should tell your doctor if:&nbsp;</p><ul><li>you are pregnant, or planning to become pregnant&nbsp;</li><li>you are breast feeding your child. APO-DOXY is not recommended in women who are breast feeding. Tetracycline&rsquo;s are excreted in human breastmilk.&nbsp;</li><li>APO-DOXY is prescribed for a child, and your child is under 8 years old. APO-DOXY is not recommended for children under 12 years of age.&nbsp;</li><li>you have or have had any other health problems especially:&nbsp;<ul><li>you have difficulty swallowing, or medical conditions such as the &nbsp;narrowing or obstruction of your esophagus (passage from your mouth to stomach) &nbsp;</li><li>you are taking any other medicines, including medicines you buy without a prescription from a pharmacy, supermarket, or health food store.</li></ul></li></ul><p>&nbsp;</p><p><strong>c- Pregnancy and breast-feeding:</strong></p><p>Doxycycline like other Tetracyclines, may form a stable calcium complex in any bone-forming tissue, though in vitro it binds calcium less strongly than other Tetracyclines. It should be anticipated that the use of APO-DOXY during tooth development (last trimester of pregnancy, during lactation, neonatal period and early childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). Though more commonly associated with long term use of Tetracyclines, this effect has also been known to occur after short courses. Enamel hypoplasia has also been reported.</p><p>&nbsp;</p><p><strong>d- Interactions with this medication:</strong></p><p>APO-DOXY should not be taken with alcohol, barbiturates, phenytoin and carbamazepine. Some medicines and APO-DOXY may interfere with each other and your doctor may wish to change dosage or directions for the following medications or may recommend other medications:&nbsp;</p><ul><li>oral anticoagulants&nbsp;</li><li>penicillin&nbsp;</li><li>bismuth subsalicylate&nbsp;</li><li>antacids containing aluminum, calcium or magnesium reduce APO-DOXY absorption and should not be given to patients taking APO-DOXY&nbsp;</li><li>iron-containing products should be taken at a different time than APO-DOXY.&nbsp;</li><li>use of APO-DOXY may reduce the effectiveness of oral contraceptives<br />&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- How to take APO-DOXY:</strong></p><p>Antibacterial drugs including APO-DOXY should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). Although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may:</p><ul><li>decrease the effectiveness of the immediate treatment and&nbsp;</li><li>increase the likelihood that bacteria will develop resistance and will not be treatable by APO-DOXY or other antibacterial drugs in the future.&nbsp;</li></ul><p>Follow your doctor&rsquo;s instructions carefully about how much APO-DOXY to take and when to take it. APO-DOXY should be taken with or after a meal. This should be swallowed with a full glass of water to avoid potential irritation or ulceration of the esophagus (passage from mouth to stomach). Remain in an upright position for a time and do not go to bed right away (at least 1-2 hours), to avoid direct irritation of the esophagus.</p><p>&nbsp;</p><p><strong>b- If you take more APO-DOXY than should:</strong></p><p>Do not take more capsules than your doctor has told you to. If you take too many capsules by accident, call your doctor, pharmacist, local poison control centre or hospital emergency department immediately.</p><p>&nbsp;</p><p><strong>c- If you forget to take APO-DOXY:</strong></p><p>If you should forget to take your capsule at the usual time, take it as soon as you remember unless it is time to take the next one. &nbsp;Continue with the remaining doses as before. &nbsp;Do not take more than one dose at a time.</p><p>&nbsp;</p><p><strong>d- While you are taking APO-DOXY:</strong></p><ul><li>Follow your doctor&rsquo;s instructions carefully, &nbsp;</li><li>Stop taking APO-DOXY immediately if you become pregnant and consult your doctor.&nbsp;</li><li>Tell your doctor and pharmacist that you are taking APO-DOXY if you are about to start taking any new medicines.&nbsp;</li><li>Do not stop taking your medicine until your doctor tells you to, even if you are feeling better.&nbsp;</li><li>Do not use APO-DOXY to treat any other medical complaints unless your doctor tells you to.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>APO-DOXY may cause side effects. &nbsp;If they occur, they are likely to be minor and temporary. &nbsp;However, some may be serious and need medical attention. APO-DOXY may cause side effects such as nausea, vomiting, diarrhea, loss of appetite, abdominal pain, pain or difficulty in swallowing, tooth discolouration and rash.&nbsp;<br />Use of APO-DOXY may increase the incidence of vaginal candidiasis (infection) and benign intercranial hypertension (high blood pressure in the brain).&nbsp;</p><p>&nbsp;</p><p>Sensitivity to sunlight and development of a sunburn reaction have occurred with some individuals taking Tetracyclines. If you plan to be exposed to direct sunlight, preventative use of a sunscreen or other physical measures are recommended. Avoid excessive sunlight or artificial ultraviolet exposure. Discontinue use if photoxicity develops (e.g. skin eruption).&nbsp;<br />Tell your doctor or pharmacist right away if you suffer from any of the following side effects while taking this medication:&nbsp;</p><ul><li>if you develop diarrhea, watery diarrhea, bloody stools, &nbsp;with or without stomach cramps and fever, contact your doctor as soon as possible.&nbsp;</li></ul><p>&nbsp;</p><p>Check with your doctor or pharmacist right away if you have any problems while taking APO-DOXY, even if you do not think the problems are connected with the medicine or are not listed in this leaflet.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep all medications out of the reach of children.</li><li>Store below 25&deg;C.&nbsp;</li><li>Protect from light.</li><li>You should not use your medication after the expiration date printed on the carton and label.<br />&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is doxycycline (as hyclate).&nbsp;</li><li>The other ingredients are lactose monohydrate, croscarmellose sodium, stearic acid, magnesium stearate. Capsule shell contains talc, gelatin, FD&amp;C Blue #1 dye, titanium dioxide, iron oxide, FD&amp;C Blue #2 dye, FD&amp;C Red #40 dye, FD&amp;C Blue #1 dye, D&amp;C Yellow #10 dye.&nbsp;<br />&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                APO-DOXY capsules are available as blue opaque body, blue opaque cap, hard gelatin capsule. Imprinted APO 100. Pale yellow powder fill.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised on 01/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ابو-دوكسي هو مضاد حيوي متعدد الاستعمالات.</p><p>يستخدم في علاج مجموعة متنوعة من الالتهابات التي تسببها سلالات حساسة من البكتيريا إيجابية الجرام وسالبة الجرام وبعض الكائنات الحية الدقيقة الأخرى.<br />ويمكن استخدامه لعلاج مجموعة واسعة من الالتهابات التي تسببها البكتيريا. وتشمل هذه الالتهاب الرئوي، وغيرها من امراض الجهاز التنفسي ، التهابات المسالك و الجهاز البولي التناسلي ، التهابات الجلد والأنسجة اللينة و التهابات المعدة والأمعاء.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- لا يؤخذ ابو-دوكسي في الحالات التالية:</strong></p><ul><li>الحساسية تجاه أيٍ من المكونات المذكورة في نهاية هذه النشرة&nbsp;</li><li>الإصابة بالوهن العضلي الوبيل (مرض مزمن في المناعة الذاتية العصبية والعضلية يسبب ضعف العضلات)</li></ul><p>&nbsp;</p><p><strong>ب- اتخاذ العناية الخاصة:</strong></p><p>ينبغي إخبار الطبيب بالحالات التالية:&nbsp;</p><ul><li dir="rtl">الحمل أو التخطيط للحمل.&nbsp;</li><li dir="rtl">الرضاعة الطبيعية. لا يوصى باستخدام ابو-دوكسيللسيدات المرضعات. تُفرز مادة تتراسيكلين في لبن الثدي البشري.&nbsp;</li><li dir="rtl">يوصف ابو-دوكسي للأطفال فوق سن 12 سنوات. لا يوصى باستخدام ابو-دوكسيفي الأطفال تحت 8 سنوات.&nbsp;</li><li dir="rtl">إذا كنت تعاني من مشكلات صحية أخرى في الوقت الحالي أو سابقًا:&nbsp;<ul><li>صعوبة في البلع، أو حالات طبية مثل تضيق أو انسداد المريء (القناة الواصلة بين الفم والمعدة) &nbsp;</li><li>إذا كنت تستخدم أدوية أخرى، بما في ذلك الأدوية التي تشتريها من الصيدلية أو متجر الأعشاب أو متجر الأغذية الصحية دون&nbsp;وصفة طبية.</li></ul></li></ul><p>&nbsp;</p><p><strong>ج- الحمل والرضاعة الطبيعية:</strong></p><p>قد يؤدي دوكسيسيكلين - مثل أنواع التتراسيكلين الأخرى - إلى تكون طبقة كالسيوم ثابتة في أي أنسجة مكونة للعظام، وعلى الرغم من ذلك فقد كان دوكسيسيكلين أقل ارتباطًا بالكالسيوم من أنواع التتراسيكلين الأخرى في التجارب المختبرية. ينبغي توقع أن يؤدي استخدام ابو-دوكسي خلال فترة نمو الأسنان (الثلث الأخير من الحمل، وأثناء الرضاعة، وفترة ما بعد الولادة والطفولة المبكرة إلى سن 8 سنوات) إلى تلون دائم للأسنان (أصفر، رمادي، بني). على الرغم من أن هذا الأثر يرتبط بشكل أكثر شيوعًا بالاستخدام طويل المدى لمادة التتراسيكلين، فقد عُلم أن هذا الأثر يحدث في الدورات العلاجية القصيرة أيضًا. كما تم الإبلاغ عن حدوث حالة نقص تنسج الميناء أيضًا.</p><p>&nbsp;</p><p><strong>د- التفاعلات مع الأدوية الأخرى:</strong></p><p>ينبغي عدم استخدام ابو-دوكسي مع الكحول والباربيتورات والفينيتوين والكاربامازبين. قد تتداخل بعض الأدوية مع ابو-دوكسي، وربما يرغب الطبيب في تغيير الجرعة أو إرشادات الاستخدام للأدوية التالية أو قد يوصي باستخدام أدوية أخرى:&nbsp;</p><ul><li>مضادات التخثر التي تؤخذ عن طريق الفم&nbsp;</li><li>البنسيلين&nbsp;</li><li>بزموت سبسالسيلات&nbsp;</li><li>تؤدي مضادات الحموضة المحتوية على الألومنيوم أو الكالسيوم أو الماغنيسيوم إلى تقليل امتصاص ابو-دوكسي ويجب عدم إعطائها للمرضى الذين يتناولون ابو-دوكسي.</li><li>ينبغي تناول المنتجات المحتوية على الحديد في أوقات غير التي يُتناول فيها ابو-دوكسي.&nbsp;</li><li>قد يؤدي استخدام ابو-دوكسي إلى تقليل فعالية موانع الحمل الفموية.<br />&nbsp;</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- كيفية تناول الدواء ابو-دوكسي:</strong></p><p>ينبغي عدم استخدام الأدوية المضادة للبكتيريا - بما في ذلك ابو-دوكسي - إلا لعلاج حالات العدوى البكتيرية فقط. وذلك لأن هذه الأدوية لا تعالج العدوى الفيروسية (مثل نزلات البرد). على الرغم من أنه من الشائع أن يشعر المريض بتحسن في وقت مبكر من الدورة العلاجية، ينبغي أن يؤخذ الدواء حسب تعليمات الطبيب تمامًا بتمام. قد يؤدي ترك جرعات أو عدم استكمال الدورة العلاجية بأكملها إلى حدوث ما يلي:</p><ul><li>تقليل فعالية العلاج المباشر و&nbsp;</li><li>زيادة احتمال تطور مقاومة البكتيريا وعدم إمكانية علاجها باستخدام ابو-دوكسي أو غيره من الأدوية المضادة للبكتيريا في المستقبل.&nbsp;</li></ul><p>&nbsp;</p><p>ينبغي اتباع تعليمات الطبيب بدقة وعناية فيما يتعلق بجرعة ابو-دوكسي التي حددها لك ومواعيد تناولها. ينبغي تناول ابو-دوكسيمع الوجبات أو بعدها. يجب ابتلاع الجرعة مع كوب كامل من الماء لتجنب حدوث تهيج أو تقرح المريء (القناة الموصلة بين الفم والمعدة). وينبغي أن يكون المريض في وضع مستقيم منتصب القامة لبعض الوقت ولا يذهب للنوم مباشرة (لمدة ساعة أو ساعتين على الأقل) وذلك لتجنب حدوث تهيج مباشر في المرئ.</p><p>&nbsp;</p><p><strong>ب- في حالة تناول جرعة زائدة من ابو-دوكسي:</strong></p><p>ينبغي عدم أخذ جرعة أكبر من التي أوصى بها الطبيب. في حالة تناول عدد كبير من الكبسولات عن طريق الخطأ, <strong>اتصل بالطبيب أو الصيدلي أو مركز مكافحة السموم المحلي أو قسم الطوارئ بالمستشفى على الفور.</strong></p><p>&nbsp;</p><p><strong>ج- في حالة نسيان تناول جرعة ابو-دوكسي:</strong></p><p>في حالة نسيان تناول الجرعة في الوقت المعتاد، ينبغي تناولها في أقرب وقت حال تذكرها إلا إذا كان موعد الجرعة التالية قد حان. &nbsp;وينبغي الاستمرار في تناول الجرعات المتبقية في مواعيدها المعتادة. &nbsp;وينبغي عدم تناول أكثر من جرعة واحدة في المرة الواحدة.</p><p>&nbsp;</p><p><strong>د- أثناء استخدام ابو-دوكسي:</strong></p><ul><li>يُرجى اتباع تعليمات الطبيب بعناية. &nbsp;</li><li>يجب التوقف عن تناول ابو-دوكسي على الفور في حالة حدوث حمل، ثم استشارة الطبيب.&nbsp;</li><li>أخبر الطبيب والصيدلي أنك تستخدم ابو-دوكسي إذا كنت ستبدأ في استخدام أي أدوية أخرى.&nbsp;</li><li>لا تتوقف عن تناول الدواء الخاص بك حتى يخبرك الطبيب بذلك، حتى لو كنت تشعر بتحسن.&nbsp;</li><li>لا تستخدم ابو-دوكسي لعلاج أي شكاوى طبية أخرى إلا إذا أخبرك الطبيب بذلك.<br />&nbsp;</li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يسبب ابو-دوكسي آثارًا جانبية. &nbsp;وهذه الآثار الجانبية تكون طفيفة ومؤقتة عادةً. &nbsp;ولكن بعض الآثار الجانبية قد تكون خطيرة وتحتاج إلى عناية طبية. قد يسبب ابو-دوكسي آثارًا جانبية مثل الغثيان، القيء، الإسهال، فقدان الشهية، ألم في البطن، ألم أو صعوبة في البلع، تغير لون الأسنان وطفح جلدي.&nbsp;<br />قد يؤدي استخدام ابو-دوكسي إلى زيادة الإصابة بداء المبيضات المهبلية (عدوى) وارتفاع ضغط الدم الحميد داخل الجمجمة (ارتفاع ضغط الدم في الدماغ).&nbsp;</p><p>&nbsp;</p><p>حدثت حالات حساسية لأشعة الشمس وحروق شمسية لدى بعض الأفراد الذين يتناولون تتراسيكلين. إذا كنت تتعرض لأشعة الشمس بشكل مباشر، فينصح باستخدام المواد الواقية من الشمس أو غيرها من التدابير الوقائية. وينبغي تجنب التعرض المفرط لأشعة الشمس أو الأشعة فوق البنفسجية الصناعية. ويجب التوقف عن تناول هذا الدواء في حالة حدوث التسمم الضوئي (على سبيل المثال الطفح الجلدي).&nbsp;<br />أخبر الطبيب أو الصيدلي على الفور إذا أُصبت بأيٍ من الآثار الجانبية التالية أثناء استخدام هذا الدواء:&nbsp;</p><ul><li dir="rtl">عند حدوث إسهال، إسهال مائي، براز دموي، مع أو بدون تقلصات في المعدة وحمى، اتصل بطبيبك على الفور.&nbsp;</li></ul><p>&nbsp;</p><p>يجب استشارة الطبيب أو الصيدلي على الفور إذا كنت تعاني من أي مشكلات أثناء استخدام ابو-دوكسي، حتى لو كنت تظن أن المشكلات لا ترتبط بالدواء أو لم ترد في هذه النشرة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>احفظ جميع الأدوية بعيدًا عن متناول الأطفال.</li><li>يخزن في درجة حرارة أقل من 25 درجة مئوية.&nbsp;</li><li>احفظه من الضوء.</li><li>يجب عدم استخدام هذا الدواء بعد انتهاء تاريخ الصلاحية المطبوع على العلبة الكرتونية والملصق التعريفي.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>المادة الفعالة هي دوكسيسيكلين على هيئة (هيكليت)</li><li>باقي المواد هي لاكتوز مونوهيدرات، كروسكرميلوز الصوديوم، حامض دهني، ستيرات الماغنيسيوم. يحتوي غلاف الكبسولة على تالك، جيلاتين، صبغة زرقاء رقم 1 حسب معيار الأغذية والعقاقير ومستحضرات التجميل (FD&amp;C)، وثاني أكسيد التيتانيوم، وأكسيد الحديد، وصبغة زرقاء رقم 2 حسب معيار الأغذية والعقاقير ومستحضرات التجميل (FD&amp;C)، وصبغة حمراء رقم 40 حسب معيار الأغذية والعقاقير ومستحضرات التجميل (FD&amp;C)، وصبغة زرقاء رقم 1 حسب معيار الأغذية والعقاقير ومستحضرات التجميل (FD&amp;C)، وصبغة صفراء رقم 10 حسب معيار الأغذية والعقاقير ومستحضرات التجميل (FD&amp;C).&nbsp;<br />&nbsp;</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر كبسولات ابو-دوكسي في شكل كبسولات جيلاتينية صلبة غير شفافة زرقاء اللون. مطبوع على الكبسولة الأحرف ورقم التركيز &laquo;APO 100&raquo;. المسحوق الداخلي لونه أصفر فاتح.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>أبوتكس إنك، تورنتو، أونتاريو، ام 9 ال 1تي9 كندا.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 01/2016

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apo-Doxy 100 mg Capsule
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-DOXY capsules contain doxycycline hyclate equivalent to 100 mg of doxycycline base. Also contains lactose monohydrate, croscarmellose sodium, stearic acid, and magnesium stearate.
Capsule shell contains gelatin, titanium dioxide, and FD&C Blue #1 dye. Supplied in plastic bottles (high density polyethylene) of 100, 250, 500, and 1000 capsules and blister of 10’s.

* Not all packs available.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Blue hard gelatin capsules containing doxycycline hyclate equivalent to 100 mg of doxycycline
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxycycline hyclate is a broad-spectrum antibiotic and is active against a wide range of Gram- negative and Gram-positive organisms. Doxycycline exerts its bacteriostatic effect by the inhibition of protein synthesis.</p><p>&nbsp;</p><p>APO-DOXY may be indicated for the treatment of:</p><p>&nbsp;</p><p><u>Pneumonia</u></p><p>Single and multilobe pneumonia and bronchopneumonia due to susceptible strains of <em>Streptococcus</em><em> pneunomiae </em>and other <em>Streptococcus</em><em> </em>spp., <em>Staphylococcus </em>spp., <em>H. influenzae </em>and <em>Klebsiella pneumoniae</em>.</p><p>&nbsp;</p><p><u>Other Respiratory Tract Infections</u></p><p>Pharyngitis, tonsillitis, sinusitis, otitis media, bronchitis caused by susceptible strains of &beta;- hemolytic <em>Streptococcus</em>, <em>Staphylococcus spp., Streptococcus pneunoniae </em>and <em>H. influenzae</em>.</p><p>&nbsp;</p><p><u>Genitourinary Tract Infections</u></p><p>Pyelonephritis, cystitis, urethritis caused by susceptible strains of <em>Klebsiella</em><em> </em>spp., <em>Enterobacter aerogenes</em>, <em>E. coli</em>, <em>Enterococcus </em>spp., <em>Staphylococcus </em>spp., <em>Streptococcus </em>spp. and gonococcal urethritis caused by <em>Neisseria gonorrhoeae.</em></p><p><em>&nbsp;</em></p><p>In adult patients with urethritis, cervicitis and vaginitis with a positive test for <em>Chlamydia</em><em> trachomatis </em>and/or <em>Ureaplasma</em><em> urealyticum</em>, clinical resolution and absence of detectable organisms have only been observed at completion of ORAL therapy with doxycycline. Relapses or reinfection can occur. In these cases, limited data suggest that some patients may derive clinical benefit from an alternative therapy. The effect on long term morbidity has not been established.</p><p>&nbsp;</p><p><u>Skin and Soft Tissue Infections</u></p><p>Impetigo, furunculosis, cellulitis, abscess, wound infections, paronychia, caused by susceptible strains of <em>Staphylococcus</em><em> aureus </em>and <em>epidermidis</em>, <em>Streptococcus </em>spp., <em>E. coli</em>, <em>Klebsiella </em>spp. and <em>Enterobacter aerogenes.</em></p><p><em>&nbsp;</em></p><p><u>Gastro-intestinal Infections</u></p><p>Caused by susceptible strains of <em>Shigella</em><em> </em>spp., <em>Salmonella </em>spp. and <em>E. coli.</em></p><p><em>&nbsp;</em></p><p>Up to 44 percent of strains of <em>Streptococcus</em><em> pyogenes </em>and 74 percent of <em>Streptococcus</em><em> faecalis </em>have been found to be resistant to tetracycline drugs.</p><p>&nbsp;</p><p>Appropriate culture and susceptibility studies should be carried out prior to initiation of therapy with APO-DOXY and if clinically indicated during treatment. Consideration may be given to the initiation of therapy before obtaining results of these tests, however modification of such treatment may be required once the results become available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.</p><p>&nbsp;</p><p><strong><u>Adults</u></strong></p><p>The recommended dosage of oral APO-DOXY for the majority of susceptible infections is a single loading dose of 200 mg on the first day of treatment followed by a maintenance dosage of 100 mg once daily at the same time each day thereafter.</p><p>In the management of more severe infections (particularly chronic infections of the urinary tract), 200 mg should be given daily throughout the treatment period.</p><p>Therapy should be continued for at least 24-48 hours after symptoms and fever have subsided. It should be noted, however, that effective antibacterial levels are usually present 24 to 36 hours following discontinuance of APO-DOXY therapy.</p><p>When used in streptococcal infections, therapy should be continued for 10 days to prevent the development of rheumatic fever or glomerulonephritis.</p><p>For treatment of uncomplicated acute gonococcal infections, the recommended dosage is 200 mg starting and 100 mg in the evening, the first day, followed by 100 mg b.i.d. for 3 days.</p><p>For treatment of uncomplicated urethral, endocervical, or vaginal infections in adults associated with <em>Chlamydia trachomatis </em>and <em>Ureaplasma urealyticum</em>: 100 mg, by mouth, twice a day for at least 10 days.</p><p>No alteration in recommended dosage schedule need be made when treating patients with impaired renal function.</p><p>&nbsp;</p><p><strong><u>Administration</u></strong></p><p>APO-DOXY should be given with or after a meal in order to minimize the possibility of gastric upset. Antacids and iron preparations impair absorption and should not be given concomitantly to patients taking oral APO-DOXY.</p><p>&nbsp;</p><p>Patients should be advised to take APO-DOXY with a full glass of water, to keep in orthostatic position after the administration and not to go to bed within 1-2 hours after the intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-DOXY is contraindicated in individuals who have shown hypersensitivity to APO-DOXY (doxycycline hyclate), and to any of its inert ingredients or to any other tetracycline, and in patients with myasthenia gravis.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Doxycycline like other tetracyclines, may form a stable calcium complex in any bone-forming tissue, though <em>in vitro </em>it binds calcium less strongly than other tetracyclines. It should be anticipated that the use of APO-DOXY during tooth development (last trimester of pregnancy, during lactation, neonatal period and early childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). Though more commonly associated with long term use of tetracyclines, this effect has also been known to occur after short courses. Enamel hypoplasia has also been reported.</p><p>&nbsp;</p><p><u>Carcinogenesis and Mutagenesis</u></p><p>Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibiotics, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors).</p><p>&nbsp;</p><p>Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in in-vitro mammalian cell assays have been reported for related antibiotics (tetracycline).</p><p>&nbsp;</p><p><u>Gastrointestinal</u></p><p>Instances of esophageal lesions (esophagitis and ulcerations), sometimes severe, have been reported in patients receiving doxycycline. The patients must be instructed to take APO-DOXY / APO- DOXY-TABS with a full glass of water, to keep in orthostatic position after the administration and not to go to bed within 1-2 hours after the intake. If symptoms such as dysphagia and retrosternal pain occur, APO- DOXY / APO-DOXY-TABS should be discontinued and an esophagic lesion must be investigated (see <strong><u>UNDESIRABLE EFFECTS</u>, <u>DOSAGE AND ADMINISTRATION</u>)</strong>. APO-DOXY should not be prescribed to patients with obstructive esophagic pathology, such as stenosis and achalasia.</p><p>&nbsp;</p><p><em>Clostridium difficile</em>-associated disease (CDAD) has been reported with use of many antibacterial agents, including doxycycline hyclate. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.</p><p>&nbsp;</p><p>Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of <em>Clostridium difficile</em>. <em>C. difficile </em>produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.</p><p>&nbsp;</p><p>If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against <em>Clostridium difficile</em>. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against <em>Clostridium difficile</em>. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases. (see <strong><u>UNDESIRABLE EFFECTS</u></strong><u>)</u></p><p>&nbsp;</p><p><u>Skin</u></p><p>Photosensitivity reaction manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with APO-DOXY, and treatment should be discontinued at the first evidence of skin erythema (see <strong><u>UNDESIRABLE</u></strong><strong><u> EFFECTS</u>)</strong>. The use of sunscreen or sunblock prior to sun or UV light exposure should be considered in patients taking APO-DOXY.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity adverse drug reactions that included, but not limited to anaphylactic reaction, angionedema, dyspnea, tachycardia, hypotension, pericarditis, urticaria, rash, erythema multiforme, Stevens-Johnson and toxic epidermal necrolysis have been reported with APO-DOXY use. Some of these reactions were serious. If an allergic reaction occurs, administration of APO-DOXY should be discontinued and appropriate therapy should be initiated.</p><p>&nbsp;</p><p>APO-DOXY has been associated with the development of autoimmune adverse drug reactions including exacerbation of systemic lupus erythematous, rash, peripheral edema, arthralgia, myalgia, serum sickness. If patients with autoimmune reactions are suspected, administration of APO-DOXY should be discontinued and liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients.</p><p>&nbsp;</p><p><u>Renal</u></p><p>The anti-anabolic action of tetracyclines may cause an increase in BUN. Studies to date indicate that this anti-anabolic effect does not occur with the use of doxycycline in patients with impaired renal function.</p><p>&nbsp;</p><p><u>Usage in Pregnancy</u></p><p>APO-DOXY should not be administered to pregnant women, unless in the judgment of the physician the potential benefit to the mother outweighs the risk to the fetus (see above WARNINGS section about use during tooth development).</p><p>&nbsp;</p><p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy.</p><p>&nbsp;</p><p><u>Usage During Lactation</u></p><p>Tetracyclines are excreted in the milk of lactating women. Accordingly the use of APO-DOXY is not recommended in women while they are breast feeding (see above <strong><u>WARNINGS</u></strong><strong><u> </u></strong>section about use during tooth development).</p><p>&nbsp;</p><p><u>Use in Newborns, Infants and Children</u></p><p>The use of APO-DOXY in children under 8 years is not recommended because safe conditions for its use have not been established (see above <strong><u>WARNINGS </u></strong>section about use during tooth development).</p><p>&nbsp;</p><p>Doxycycline hyclate like other tetracyclines forms a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.</p><p>&nbsp;</p><p>APO-DOXY should, therefore, not be used in these age groups unless other drugs are unlikely to be effective or are contraindicated.</p><p>&nbsp;</p><p>In clinical studies to date, administration of doxycycline hyclate did not lead to increased serum levels nor to an increase in the serum half-life of doxycycline in patients with impaired renal function.&nbsp; Modification of doxycycline hyclate dosage for these patients is not necessary. Although no evidence of increased toxicity has been observed in such patients, the potential for increased hepatic or other toxicity should be considered until further data on the metabolic fate of doxycycline under these conditions become available.</p><p>&nbsp;</p><p>Concurrent administration of APO-DOXY with agents known to be hepatotoxic should be avoided.</p><p>&nbsp;</p><p>The use of antibiotics may occasionally result in overgrowth of non-susceptible organisms including fungi; thus, observation of the patient is essential.</p><p>&nbsp;</p><p>Patients should be advised that the use of doxycycline might increase the incidence of vaginal candidiasis.</p><p>&nbsp;</p><p>Fontanelle bulging in infants and benign intracranial hypertension in adults have been reported in individuals receiving full therapeutic dosages. Although the mechanism of this phenomenon is unknown the signs and symptoms have disappeared rapidly upon cessation of treatment with no sequelae (see <strong><u>UNDESIRABLE EFFECTS</u></strong>).</p><p>&nbsp;</p><p>Cases of esophageal injury consisting of esophagitis and esophageal ulceration have been reported in patients receiving doxycycline hyclate orally. Most of these patients took medication immediately before going to bed and/or without adequate amount of fluid (see <strong><u>DOSAGE</u></strong><strong><u> AND</u> <u>ADMINISTRATION</u></strong>). If this should occur, APO-DOXY should be discontinued until healing occurs. Administration of antacids and/or cimetidine has provided relief in the treatment of such cases. TO REDUCE THE RISK OF ESOPHAGEAL INJURY, PATIENTS SHOULD BE ADVISED TO TAKE APO-DOXY OR APO-DOXY-TABS WITH AN ADEQUATE AMOUNT OF FLUID WHILE STANDING OR SITTING UPRIGHT. APO-DOXY should not be given at bedtime.</p><p>&nbsp;</p><p>In long term therapy with APO-DOXY, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic studies should be performed. Liver function tests should be carried out at regular intervals on patients receiving high doses for prolonged periods of time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-DOXY should be given with caution to patients receiving oral anticoagulants. Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</p><p>Antacids containing aluminum, calcium or magnesium impair absorption and should not be given to patients taking APO-DOXY.</p><p>&nbsp;</p><p>The concurrent use of Doxycycline hyclate with alcohol, barbiturates, phenytoin and carbamazepine (hepatic enzyme inducers) has been reported to result in a reduction of plasma half-life of doxycycline, thereby reducing the antimicrobial effectiveness of Doxycycline<strong>.</strong><strong> </strong>This effect may last for several days after discontinuation of therapy with the interacting agent. Therefore, consideration should be given to re-adjustment of the daily dose of APO-DOXY when administered concomitantly with alcohol and with drugs known to be enzyme inducers.</p><p>&nbsp;</p><p>It has been reported that concurrent administration of ferrous sulphate (iron) lowered serum concentrations of doxycycline given orally and shortened the serum half-life after a single intravenous injection. In the event that iron and iron-containing products have to be given during treatment with APO-DOXY the interval between administration of each drug should be as wide as possible.</p><p>&nbsp;</p><p>It has been reported that when subsalicylate bismuth was given simultaneously and as a multiple- dose regimen before oral doxycycline hyclate there was a reduced bioavailability of doxycycline. Also peak serum concentrations of doxycycline were significantly decreased when subsalicylate bismuth was given 2 hours before oral doxycycline but not when given 2 hours after oral doxycycline. Therefore subsalicylate bismuth should not be taken during therapy with oral APO- DOXY<strong>.</strong></p><p><strong>&nbsp;</strong></p><p>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving APO-DOXY or any other tetracycline, in conjunction with penicillin.</p><p>There have been anecdotal reports that concurrent use of tetracyclines may render oral contraceptives less effective.</p><p>The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.</p><p>&nbsp;</p><p><u>Drug Laboratory Test Interactions</u></p><p>False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Use in Pregnancy (Category D)</strong></p><p>APO-DOXY should not be administered to pregnant women, unless in the judgment of the physician the potential benefit to the mother outweighs the risk to the fetus.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>Tetracyclines are excreted in the milk of lactating women. Accordingly the use of APO-DOXY is not recommended in women while they are breast feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>​​​​​​​Visual disturbances such as blurring of vision may occur during treatment with doxycycline and in such cases; patients must be informed to refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>GASTROINTESTINAL</u></p><p>As with other broad spectrum antibiotics administered orally and parenterally, gastro-intestinal disturbances such as anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, stomatitis, proctitis and enterocolitis, may occur, but have rarely been sufficiently troublesome to warrant discontinuation of therapy with doxycycline hyclate. Abdominal pain, dyspepsia (heartburn/gastritis), pseudomembranous colitis, <em>C. difficile </em>diarrhea and inflammatory lesions (with monilial overgrowth) in the anogenital region have also been reported. Due to oral doxycycline&rsquo;s virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent.</p><p>&nbsp;</p><p>Cases of esophagitis and esophageal ulcerations, sometimes severe, in patients receiving capsule and tablet form of doxycycline hyclate have been reported (see <strong><u>WARNINGS</u></strong><strong><u> AND</u> <u>PRECAUTIONS, DOSAGE AND ADMINISTRATION</u></strong>).</p><p>&nbsp;</p><p><u>AUTONOMIC NERVOUS SYSTEM</u></p><p>Flushing.</p><p>&nbsp;</p><p><u>HYPERSENSITIVITY</u></p><p>Hypersensitivity reactions consisting of urticaria, angioedema, anaphylactic reaction, anaphylactoid reaction, Henoch-Schonlein Purpura, dyspnea, hypotension, pericarditis, peripheral edema, serum sickness, tachycardia and exacerbation of systemic lupus erythematosus have been reported.</p><p>&nbsp;</p><p><u>SKIN</u></p><p>Maculopapular and erythematous rashes, photosensitivity reaction, photo-onycholysis, erythema multiforme, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis have been reported.</p><p>Exfoliative dermatitis has also been reported but is uncommon (see <strong><u>WARNINGS, skin</u></strong>).</p><p>&nbsp;</p><p><u>MUSCULO-SKELETAL</u></p><p>Arthralgia and myalgia.</p><p>&nbsp;</p><p><u>CENTRAL NERVOUS SYSTEM</u></p><p>Headache, fontanelle bulging in infants and benign intracranial hypertension in adults. In relation to benign intracranial hypertension, symptoms included blurring of vision, scotomata and diplopia.</p><p>Permanent visual loss has been reported (see <strong><u>WARNINGS</u></strong><strong><u> AND PRECAUTIONS</u></strong>).</p><p>&nbsp;</p><p><u>LIVER/BILIARY</u></p><p>There have been reports of hepatotoxicity (including hepatic failure, autoimmune hepatitis and cholestasis) and hepatic function abnormal. As with other tetracyclines, hepatitis, elevation of SGOT or SGPT values have been reported, the significance of which is not known.</p><p>&nbsp;</p><p><u>HAEMATOLOGIC</u></p><p>Hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia, leukopenia. <u>IMMUNE SYSTEM DISORDERS</u></p><p>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) <u>HEARING/VESTIBULAR</u></p><p>Tinnitus.</p><p>&nbsp;</p><p><u>INVESTIGATIONS </u>(Renal Function Analyses)</p><p>Blood urea increased (apparently dose related) has been reported.</p><p>&nbsp;</p><p><u>UROGENITAL</u></p><p>Vaginal candidiasis (see <strong><u>WARNINGS AND PRECAUTIONS</u></strong>)</p><p>&nbsp;</p><p><u>OTHERS</u></p><p>When given over prolonged periods tetracyclines have been reported to produce brown- black microscopic discolouration of the thyroid gland. Abnormalities of thyroid function have not been shown to date (see <strong><u>TOXICOLOGY,</u></strong><strong><u> </u></strong>Subacute Toxicity).</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><ul><li>Saudi Arabia:</li></ul><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</li><li>Toll-free: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul></td></tr></tbody></table><ul><li>Other GCC States:</li></ul><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Specific information on symptoms or treatment of overdosage with doxycycline hyclate is not available. In case of overdosage, discontinue medication. Treatment, therefore, should be symptomatic and gastric lavage may be considered for overdosage with the oral preparation. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</p><table style="width:603px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="width:600px"><p>For management of suspected drug overdose contact your regional Poison Control Centre</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxycycline is a broad spectrum antibiotic and has been shown to be active <em>in vitro </em>against the following Gram-negative, Gram-positive and other microorganisms:</p><p>&nbsp;</p><p><em>Staphylococcus</em><em> </em><em>aureus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><em>Klebsiella</em><em> </em><em>pneumoniae</em><em> </em></p><p><em>Staphylococcus </em><em>epidermidis</em><em> (albus)</em></p><p><em>Streptococcus</em><em> </em><em>pyogenes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><em>Salmonella</em><em> </em><em>typhi</em></p><p><em>Streptococcus</em><em> faecalis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><em>Salmonella</em><em> typhimurium</em></p><p><em>Streptococcus</em><em> </em><em>pneumoniae&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><em>Salmonella</em><em> </em><em>enteriditis</em></p><p><em>Streptococcus</em><em> </em><em>viridans&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><em>Shigella </em><em>sonnei</em></p><p><em>Listeria</em><em> </em><em>monocytogenes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><em>Shigella</em><em> </em><em>flexneri</em></p><p><em>Corynebacterium</em><em> diphtheriae</em><em> </em></p><p><em>Bacillus</em><em> </em><em>anthracis</em></p><p><em>Bacillus</em><em> </em><em>subtilis</em><em> </em></p><p><em>Neisseria</em><em> </em><em>gonorrhoeae</em><em> </em></p><p><em>Neisseria</em><em> </em><em>catarrhalis</em><em> </em></p><p><em>Escherichia</em><em> </em><em>coli</em><em> </em></p><p><em>Enterobacter</em><em> </em><em>aerogenes</em></p><p><em>Pseudomonas</em><em> </em><em>aeruginosa</em><em> </em></p><p><em>Haemophilus</em><em> </em><em>influenzae</em><em> </em></p><p><em>Serratia</em><em> </em>spp.</p><p><em>Brucella</em><em> </em>spp.</p><p><em>Proteus </em>spp.</p><p><em>Pasteurella</em><em> </em>spp.</p><p><em>Mycoplasma</em><em> </em><em>pneumoniae</em><em> </em></p><p><em>Chlamydia</em><em> </em><em>trachomatis</em><em> </em></p><p><em>Ureaplasma</em><em> </em><em>urealyticum</em></p><p>The drugs in the tetracycline class have closely similar antimicrobial spectra, and cross- resistance among them is common.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The Kirby-Bauer method of disc susceptibility testing (using the 30 &micro;g doxycycline disc) and dilution susceptibility should be interpreted according to the criteria in <strong><u>TABLE 1</u></strong>.</p><p>&nbsp;</p><p><strong><u>TABLE</u></strong><strong><u> 1</u></strong></p><p><strong>&nbsp;</strong><u>SUSCEPTIBILITY TEST</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ZONE DIAMETER</p><p>(30 &micro; doxycycline disc) mm</p></td><td style="vertical-align:top"><p>M.I.C.</p><p>mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>&ge; 16</p></td><td style="vertical-align:top"><p>&le; 4</p></td></tr><tr><td style="vertical-align:top"><p>Intermediate</p></td><td style="vertical-align:top"><p>13-15</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&le; 12</p></td><td style="vertical-align:top"><p>&ge;16</p></td></tr></tbody></table><p>&nbsp;</p><p>Serum levels of doxycycline administered orally follow a similar pattern to those obtained with equivalent dosages administered intravenously as shown in <strong><u>TABLE 2</u>. </strong>Peak serum levels were slightly higher and occurred earlier following intravenous administration than for oral administration (see <strong><u>TABLE 2</u>)</strong>.</p><p>&nbsp;</p><p><strong><u>TABLE</u></strong><strong><u> 2</u></strong></p><p>Serum levels (mg/L) after oral and I.V. infusion over 60 minutes (0.5 mg/mL) of a total daily dose of 200 mg of doxycycline hyclate on the first day (100 mg every 12 hours) and a dose of 100 mg on the second and third day of administration (22 Male Volunteers/Group).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Time (hr: min)</p></td><td style="vertical-align:top"><p>Mean Serum Level I.V.</p></td><td style="vertical-align:top"><p>Mean Serum Level Capsules</p></td><td style="vertical-align:top"><p>p</p></td></tr><tr><td style="vertical-align:top"><p>0:05</p></td><td style="vertical-align:top"><p>2.455</p></td><td style="vertical-align:top"><p>0.000</p></td><td style="vertical-align:top"><p>&lt;.001</p></td></tr><tr><td style="vertical-align:top"><p>1:00</p></td><td style="vertical-align:top"><p>1.608</p></td><td style="vertical-align:top"><p>1.206</p></td><td style="vertical-align:top"><p>&lt;.01</p></td></tr><tr><td style="vertical-align:top"><p>2:00</p></td><td style="vertical-align:top"><p>1.551</p></td><td style="vertical-align:top"><p>1.643</p></td><td style="vertical-align:top"><p>&lt;.01</p></td></tr><tr><td style="vertical-align:top"><p>3:00</p></td><td style="vertical-align:top"><p>1.421</p></td><td style="vertical-align:top"><p>1.482</p></td><td style="vertical-align:top"><p>&lt;.01</p></td></tr><tr><td style="vertical-align:top"><p>16:00</p></td><td style="vertical-align:top"><p>1.131</p></td><td style="vertical-align:top"><p>1.124</p></td><td style="vertical-align:top"><p>&lt;.01</p></td></tr><tr><td style="vertical-align:top"><p>11:00</p></td><td style="vertical-align:top"><p>0.800</p></td><td style="vertical-align:top"><p>0.815</p></td><td style="vertical-align:top"><p>&lt;.01</p></td></tr><tr><td style="vertical-align:top"><p>13:00</p></td><td style="vertical-align:top"><p>2.397</p></td><td style="vertical-align:top"><p>1.107</p></td><td style="vertical-align:top"><p>&lt;.001</p></td></tr><tr><td style="vertical-align:top"><p>15:00</p></td><td style="vertical-align:top"><p>2.130</p></td><td style="vertical-align:top"><p>2.000</p></td><td style="vertical-align:top"><p>&lt;.001</p></td></tr><tr><td style="vertical-align:top"><p>24:00</p></td><td style="vertical-align:top"><p>1.468</p></td><td style="vertical-align:top"><p>1.663</p></td><td style="vertical-align:top"><p>.088</p></td></tr><tr><td style="vertical-align:top"><p>35:00</p></td><td style="vertical-align:top"><p>1.734</p></td><td style="vertical-align:top"><p>1.725</p></td><td style="vertical-align:top"><p>.088</p></td></tr><tr><td style="vertical-align:top"><p>48:00</p></td><td style="vertical-align:top"><p>1.159</p></td><td style="vertical-align:top"><p>1.078</p></td><td style="vertical-align:top"><p>.088</p></td></tr><tr><td style="vertical-align:top"><p>48:05</p></td><td style="vertical-align:top"><p>3.658</p></td><td style="vertical-align:top"><p>1.124</p></td><td style="vertical-align:top"><p>&lt;.001</p></td></tr><tr><td style="vertical-align:top"><p>49:00</p></td><td style="vertical-align:top"><p>2.945</p></td><td style="vertical-align:top"><p>2.147</p></td><td style="vertical-align:top"><p>&lt;.001</p></td></tr><tr><td style="vertical-align:top"><p>50:00</p></td><td style="vertical-align:top"><p>2.848</p></td><td style="vertical-align:top"><p>2.406</p></td><td style="vertical-align:top" rowspan="12"><p>.056</p></td></tr><tr><td style="vertical-align:top"><p>51:00</p></td><td style="vertical-align:top"><p>2.760</p></td><td style="vertical-align:top"><p>2.436</p></td></tr><tr><td style="vertical-align:top"><p>54:00</p></td><td style="vertical-align:top"><p>2.150</p></td><td style="vertical-align:top"><p>1.989</p></td></tr><tr><td style="vertical-align:top"><p>59:00</p></td><td style="vertical-align:top"><p>1.665</p></td><td style="vertical-align:top"><p>1.516</p></td></tr><tr><td style="vertical-align:top"><p>72:00</p></td><td style="vertical-align:top"><p>1.021</p></td><td style="vertical-align:top"><p>0.945</p></td></tr><tr><td style="vertical-align:top"><p>83:00</p></td><td style="vertical-align:top"><p>0.700</p></td><td style="vertical-align:top"><p>0.709</p></td></tr><tr><td style="vertical-align:top"><p>96:00</p></td><td style="vertical-align:top"><p>0.426</p></td><td style="vertical-align:top"><p>0.399</p></td></tr><tr><td style="vertical-align:top"><p>107:00</p></td><td style="vertical-align:top"><p>0.247</p></td><td style="vertical-align:top"><p>0.234</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mean area</p></td><td style="vertical-align:top"><p>Mean area</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>Capsules</p></td></tr><tr><td style="vertical-align:top"><p>AUC (mg&middot;h/L)</p></td><td style="vertical-align:top" rowspan="2"><p>138</p></td><td style="vertical-align:top" rowspan="2"><p>128</p></td></tr><tr><td style="vertical-align:top"><p>0-107 hr</p></td></tr></tbody></table><p>Where no p is stated, p&gt;.10</p><p>&mdash; time of dosing</p><p>Doxycycline was rapidly and almost completely absorbed following oral administration. The absorption of doxycycline was not significantly influenced by ingestion of food or milk (see <u>TABLE 3</u>).</p><p>&nbsp;</p><p><strong><u>TABLE</u></strong><strong><u> 3</u></strong></p><p>Effect&nbsp;of&nbsp;Food or Milk&nbsp;on&nbsp;Absorption of&nbsp;a Single Oral Dose of Doxycycline 100 mg as Hyclate (5 Male Volunteers/Group).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="4"><p>AVERAGE SERUM LEVELS (mg/L)</p></td></tr><tr><td style="vertical-align:top"><p>Hours</p></td><td style="vertical-align:top"><p>Breakfast</p></td><td style="vertical-align:top"><p>Fasting</p></td><td style="vertical-align:top"><p>6 oz. milk</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.966</p></td><td style="vertical-align:top"><p>1.004</p></td><td style="vertical-align:top"><p>1.081</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1.188</p></td><td style="vertical-align:top"><p>1.377</p></td><td style="vertical-align:top"><p>1.325</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1.269</p></td><td style="vertical-align:top"><p>1.296</p></td><td style="vertical-align:top"><p>1.244</p></td></tr></tbody></table><table style="width:265px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:55px"><p>5</p></td><td style="vertical-align:top; width:73px"><p>1.036</p></td><td style="vertical-align:top; width:62px"><p>1.133</p></td><td style="vertical-align:top; width:72px"><p>1.046</p></td></tr><tr><td style="vertical-align:top; width:55px"><p>8</p></td><td style="vertical-align:top; width:73px"><p>0.973</p></td><td style="vertical-align:top; width:62px"><p>0.936</p></td><td style="vertical-align:top; width:72px"><p>0.885</p></td></tr><tr><td style="vertical-align:top; width:55px"><p>12</p></td><td style="vertical-align:top; width:73px"><p>0.738</p></td><td style="vertical-align:top; width:62px"><p>0.801</p></td><td style="vertical-align:top; width:72px"><p>0.686</p></td></tr><tr><td style="vertical-align:top; width:55px"><p>24</p></td><td style="vertical-align:top; width:73px"><p>0.498</p></td><td style="vertical-align:top; width:62px"><p>0.528</p></td><td style="vertical-align:top; width:72px"><p>0.475</p></td></tr></tbody></table><p>&nbsp;</p><p>Doxycyline is approximately 93% protein bound. The serum half-life of doxycycline is 18 hours. Doxycycline is excreted in the urine (approximately 35-40% of the administered dose) and in the bile. The volume of distribution is approximately 0.7 L/kg. Hemodialysis does not alter the serum half-live.</p><p>Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal renal function (creatinine clearance about 75 mL/min.). This percentage excretion may fall to a range as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min.). &nbsp;The serum half-life of doxycycline is not increased, nor does it accumulate in the blood of patients with impaired renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a)&nbsp; <u>Acute</u><u> </u><u>Toxicity:</u></strong></p><p>The acute oral and parenteral toxicity of doxycycline in mice, rats and dogs are as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>LD50&nbsp;(95% Confidence Limits) mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ORAL</p></td><td style="vertical-align:top"><p>I.V.</p></td></tr><tr><td style="vertical-align:top"><p>Mice</p></td><td style="vertical-align:top"><p>1,900 (1696-2128)</p></td><td style="vertical-align:top"><p>241 (230-253)</p></td></tr><tr><td style="vertical-align:top"><p>Rats</p></td><td style="vertical-align:top"><p>&gt;2,000</p></td><td style="vertical-align:top"><p>228 (202-258)</p></td></tr><tr><td style="vertical-align:top"><p>Dogs</p></td><td style="vertical-align:top"><p>&gt;500</p></td><td style="vertical-align:top"><p>&gt;100</p></td></tr></tbody></table><p>The intraperitoneal LD50&#39;s of doxycycline in weanling and newborn rats are 262 (222-309) and 300 (275-327) mg/kg, respectively.</p><p>&nbsp;</p><p><strong>b)<u> </u><u>Subacute</u><u> Toxicity:</u></strong></p><p>One to 2 1/2 - month subacute toxicity studies were conducted in rats, hamsters, dogs and monkeys. &nbsp;Doxycycline induced a yellow fluorescence (under ultraviolet light) of bone, teeth, kidney and/or liver, in all animal species tested. &nbsp;In rats, doxycycline produced no toxic effects in doses of up to 500 mg/kg/day for 30 days. In hamsters, doxycycline in dosages of 500 or 250 mg/kg/day produced weight loss and early death, but the 50 mg/kg level (for 30 days) was nontoxic. In dogs, doxycycline in dosages of 250 mg/kg/day for one month produced discoloration of the thyroid gland with the presence of intracytoplasmic granules in follicular acini and occasional amorphous body formation within follicular colloid.</p><p>Certain biochemical, functional and histological changes of the liver occurred in the dogs (but not in the rats, hamsters, or monkeys) receiving doxycycline for 30 days at dosage levels of 250 and 50 mg/kg/day, but not at the 25 mg/kg/day level. &nbsp;The biochemical changes in the blood were elevations of alkaline phosphatase, SGPT and/or BSP retention. Histologic changes were confined to bile ductular proliferation and hepatocellular intracytoplasmic inclusion bodies and Kupffer cells swollen with PAS-positive granular material. These changes in the dog were reversible upon drug withdrawal.</p><p>Monkeys which received doxycycline at dosages of 25 and 50 mg/kg/day for 1 1/2 to 2 &frac12; months showed mild yellow ultraviolet fluorescence of liver, kidney and bone, and the presence of small amounts of intracytoplasmic granular material in the thyroid gland.</p><p>&nbsp;</p><p><strong>c)&nbsp; <u>Chronic</u><u> </u><u>Toxicity:</u></strong></p><p>In an 18-month chronic toxicity study, rats were fed diets containing doxycycline at levels to provide daily drug intake of 500, 250, 50 and 0 mg/kg. Slight depression of weight gains in some rats receiving the 500 mg/kg/day dose occurred during the middle third of the study.&nbsp; The usual yellow ultraviolet fluorescence of bone, teeth and/or kidneys was seen in rats receiving all levels of doxycycline for 6, 12 or 18 months. Dark to light brown discoloration of the thyroid gland was also noted in rats receiving doxycycline for 12 months at levels of 500 and 250 mg/kg/day, and at 18 months at all levels. The only other change noted was depletion of hepatic glycogen in four rats receiving the highest dose level for 12 months.</p><p>&nbsp;</p><p>Beagle dogs received doxycycline at levels of 10 and 100 mg/kg, six days per week. &nbsp;Moderate to marked elevations of alkaline phosphatase and SGPT (occasionally SGOT) were observed in animals receiving doxycycline, 100 mg/kg/day. One of two dogs receiving doxycycline, 100 mg/kg/day, displayed mild bile ductular proliferation and hepatocellular inclusion bodies after 5 months (biopsy sample) and 12 months (necropsy sample). Administration of doxycycline for 5 &nbsp;and 12 months at a level of 100 mg/kg/day and for 12 months at a level of 10 mg/kg caused black and brownish discoloration of the thyroid gland, respectively, with intracytoplasmic granules. Other changes included vasodilatation and focal areas of necrosis of the mucosa of the pyloric and &nbsp;fundic stomach of dogs, and yellow ultraviolet fluorescence of teeth and bones of animals at 100 mg/kg/day dose levels of doxycycline.</p><p>&nbsp;</p><p>Additional groups of 4 beagles each received doxycycline in dosages of 5, 1 and 0 mg/kg/day for 6 months. The only abnormal findings were slight elevations of SGPT values in 3 dogs at the 5 mg/kg level at 180 days.</p><p>&nbsp;</p><p>In a one year chronic toxicity study, groups of four rhesus monkeys each received doxycycline in oral doses of 0, 5, 25 and 50 mg/kg/day, respectively. &nbsp;Oral dosage of 100 mg/kg produced severe gastrointestinal symptoms, e.g., vomiting and diarrhea. In one out of 4 monkeys receiving the 50 mg/kg/day dose, occasional anorexia and diarrhea were observed during the first six months.</p><p>&nbsp;</p><p>Significant pathologic changes noted in monkeys sacrificed after receiving doxycycline for 1 year at dose levels of 50 mg/kg/day were: &nbsp;1) grossly, very light brown discoloration of the thyroid gland in one of the four monkeys, and 2) microscopically, brownish intracytoplasmic inclusions in the acinar cells of thyroid follicles of three out of four monkeys. Bone and dentin exhibited slight to moderate ultraviolet fluorescence.</p><p>&nbsp;</p><p>Two monkeys, in another study, receiving the 25 mg/kg/day dosage, were sacrificed after 6 and 8 months on test, respectively. &nbsp;Significant gross and histopathologic findings were slight yellow ultraviolet fluorescence of the endosteum and periosteum of bone, and microscopic appearance of small amounts of granular intracytoplasmic material in the acinar cells of thyroid follicles.</p><p>&nbsp;</p><p>The highlights of the chronic toxicity studies can be summarized as follows:</p><ol><li>Discoloration of the thyroid gland, with deposition of intracytoplasmic granules in the acinar cells of the follicle. Thyroid function, however, did not seem to be affected. This phenomenon appears to be a result of the interaction of the antibiotic with the active iodinating system of the gland.</li><li>Yellow staining of bones and teeth, which is thought to be due to formation of a tetracycline- calcium-phosphate complex.</li></ol><p>&nbsp;</p><p>Otherwise doxycycline was well tolerated by the rat and monkey at doses up to and including 500 and 50 mg/kg/day for 18 and 12 months, respectively. In dogs, however, repeated daily oral administration of large doses of doxycycline resulted in certain hepatic functional and histopathologic changes which are reversible after drug withdrawal. No adverse hepatic effects were noted in the hamster (1 month), rats (18 months) or monkeys (12 months) for doses up to and including 500, 500 and 50 mg/kg/day, respectively. &nbsp;In view of this and in view of the lack of notable toxicity in our wide human clinical program, it is our opinion that this is a species specific phenomenon, for the dog only.</p><p>&nbsp;</p><p><u><strong>d) Reproduction and Teratogenic Studies:</strong></u></p><p>Doxycycline has no teratologic effects in rats, rabbits or monkeys.</p><p>Breeding rats received doxycycline by gavage in doses of 50 and 250 mg/kg/day prior to and throughout two consecutive litters. There was no evidence that doxycycline interfered with the reproductive process in rats. Pregnant female white New Zealand rabbits received doxycycline orally in doses of 8 and 40 mg/kg/day, respectively, from day 8 to day 16 of pregnancy. Spina bifida and partial anencephaly in one pup each in the control and the 8 mg/kg group, respectively, are believed to be spontaneous and drug-induced. In teratogenic studies using a limited number of monkeys, doxycycline, in doses ranging from 1 to 50 mg/kg/day, did not produce any teratologic effects.</p><p>&nbsp;</p><p><u>Doxycycline</u><u> </u><u>Monohydrate</u></p><p>With bulk doxycycline monohydrate administered in a 10% aqueous suspension, the oral LD50 for albino male mice was greater than 5000 mg/kg.</p><p>&nbsp;</p><p><u>DoxycycIine</u><u> </u><u>Hyclate</u><u> with Ascorbic Acid</u></p><p>Studies in mice and rats showed the LD50 of doxycycline (as hyclate) I.V to be 75 mg/kg in mice and 88 mg/kg in rats of doxycycline (using a preparation of doxycycline hyclate equivalent to 100 mg of doxycycline with 480 mg of ascorbic acid as a sterile powder). No signs of drug toxicity were seen in dogs receiving 20 to 21 daily doses of doxycycline (as hyclate) I.V. at a dose level of 5 mg/kg when administered as a 0.5% solution at a rate of 1 mg/kg/min. Dogs receiving 14, 16 or 17 daily intravenous doses of 10 mg doxycycline (as hyclate) I.V. per kg of bodyweight, or 4 daily 60 minute infusions of 300 mg doxycycline (as hyclate) I.V.<em>,</em><em> </em>or 300 mg degraded doxycycline (as hyclate) I.V. evidenced serum alkaline phosphatase and serum glutamic pyruvic transaminase elevations. No morphological basis for these enzyme elevations was established although moderate bile ductular proliferation was seen in 1 of 2 dogs receiving 4 daily intravenous infusions of degraded doxycycline (as hyclate) I.V. In 8 dogs receiving daily intravenous doses of 10 mg doxycycline (as hyclate) I.V./kg/day (0.5% solution), 5 of 24 vessels used for injections evidenced degrees of thrombosis with recanalization. Thrombosis in 3 of 6 sites occurred in 2 dogs receiving infusions of degraded doxycycline (as hyclate) I.V. (30 mg/kg-0.5% solution). Injection site thrombosis did not occur in 6 dogs (18 sites) receiving daily doses of 5 mg doxycycline (as hyclate) I.V./kg bodyweight administered as a 0.5% solution at a rate of 1 mg/kg/min (approximately 1 mL/min). Studies to date indicate that the maximum tolerated intravenous daily dose of doxycycline (as hyclate) I.V. in dogs for 21 consecutive &nbsp;days &nbsp;is &nbsp;5 &nbsp;mg/kg/day &nbsp;when &nbsp;administered &nbsp;as &nbsp;a 0.5% solution at a rate of 1 mg/kg/min.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td style="vertical-align:top"><p>lactose monohydrate</p></td></tr><tr><td style="vertical-align:top"><p>croscarmellose sodium</p></td></tr><tr><td style="vertical-align:top"><p>stearic acid</p></td></tr><tr><td style="vertical-align:top"><p>magnesium stearate</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C. Store in original package and protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary packaging: Blister</p><p>Secondary packaging: Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2015.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>